+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy



Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy



Targeted Oncology 10(4): 517-522



We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGFR-TKIs) for late relapsing (>5 years) metastatic renal cell carcinoma (mRCC). Data were collected from 13 Italian centers involved in the treatment of metastatic RCC. Late relapse was defined as >5 years after initial radical nephrectomy. One hundred fifty-one patients were included in this analysis. Among them, MSKCC risk score was favorable in 68 %, intermediate in 29 %, and poor in 3 %. Fifty-six patients (37 %) had NLR ≥3 at the start of VEGFR-TKI therapy (group A), while 95 had lower NLR (63 %, group B). The median overall survival (OS) was 28.8 months in group A and 68.7 months (95 % confidence interval (CI) 45.3-NA) in group B (p < 0.001). The median progression-free survival (PFS) was 15.8 months in group A and 25.1 months in group B (p = 0.03). At multivariate analysis, MSKCC risk group and NLR were independent prognostic factors for both OS and PFS. Pretreatment NLR is an independent prognostic factor for patients with late relapsing mRCC treated with first-line VEGFR-TKIs. A better characterization of baseline immunological impairment may optimize the management of this RCC subpopulation.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637139

Download citation: RISBibTeXText

PMID: 25559290

DOI: 10.1007/s11523-014-0356-3


Related references

Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Medical Oncology 30(2): 556, 2013

Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy. Oncology Letters 8(2): 881-885, 2014

The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b. Journal of Clinical Oncology 10(7): 1153-1157, 1992

Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clinical Genitourinary Cancer 11(3): 311-315, 2014

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet. Oncology 16(3): 293-300, 2015

Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer 15(1): 100-111, 2016

Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series. Plos One 10(2): E0118022, 2016

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World Journal of Urology 34(8): 1067-1072, 2017

Prognostic factors and associated models for metastatic renal cell carcinoma treated with targeted therapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 36(4): 450-453, 2015

Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan. Molecular and Clinical Oncology 3(3): 601-606, 2015

Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. International Urology and Nephrology 48(6): 985-992, 2017

Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy. Clinical Genitourinary Cancer 16(4): E927-E933, 2018

Prognostic significance of nephrectomy in patients with metastatic renal cell carcinoma treated with first-line systemic therapy: A 10-year retrospective analysis according to MSKCC and Heng risk criteria. European Urology Supplements 15(13): E1752-E1753, 2016

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model. Urologic Oncology 35(2): 39.E19-39.E28, 2016

Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma. Progres en Urologie 24(9): 563-571, 2015